ATC Group: A03AB02 Glycopyrronium bromide

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for functional gastrointestinal disorders
3
DRUGS FOR FUNCTIONAL BOWEL DISORDERS
4
Synthetic anticholinergics, quaternary ammonium compounds
5
A03AB02
Glycopyrronium bromide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
3 mg
PAREN - Parenteral
3 mg
RECTAL - Rectal
3 mg

Active ingredients

Active Ingredient
Description

Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.

Medicines in this ATC group

Drug
Countries

United Kingdom

Canada United States

Austria Estonia Finland New Zealand South Africa ...

Finland Ireland

Austria Estonia Finland Ireland Lithuania ...

Related product monographs

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US
Structured Product Labeling (SPL)
US
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
IE
Summary of Product Characteristics (SPC)
UK